Trial Profile
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Motesanib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONET1
- Sponsors Amgen
- 16 Dec 2021 This trial has been completed in France (End Date: 14 Dec 2012), according to European Clinical Trials Database record.
- 14 Aug 2012 Planned end date changed from 1 Jul 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 14 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.